Bradykinin inhibition in COVID-19: a randomised, double-blind trial of icatibant versus placebo
Year: 2025
Type: conference-abstract
Abstract: Introduction: At an early stage of infection, COVID-19 causes cough, dyspnoea, loss of taste/smell and oedema seen as infiltrates on chest imaging. Coagulopathy, thrombosis and hypotension can occur. These features may be due to the contact-kinin system which triggers clotting and produces vasoactive bradykinin. Hypothesis There is excess accumulation of bradykinin in symptomatic COVID-19. Bradykinin causes oedema in the lungs, leading to hypoxia. It also causes vasodilation and cytokine release. Aim: To inhibit bradykinin in early stage hypoxic COVID-19 patients. Methods: Hypoxic PCR positive patients with symptoms ≤7 days were randomised to a single dose of bradykinin antagonist (icatibant 30mg) or placebo subcutaneously. Patients/investigators were blinded to treatment. Arterial blood sampling and cardiovascular (CVS) measurements were completed at baseline and 3 hours post treatment. The primary outcome was change in the Alveolar-arterial oxygen (A-a O2) gradient. The secondary outcome was change in CVS measurements. Results: 14 patients received icatibant and 16 placebo. A-a O2 gradient decreased by 0.09kPa (p=0.772) with icatibant (n=14) and increased by 0.07kPa (p=0.773) with placebo. Change between groups was 0.16kPa (p=0.61). MAP increased by 4.21mmHg (p=0.13) for icatibant and 3.44mmHg (p=0.16) for placebo. Change between groups was 0.77mmHg (p=0.91). Conclusion: This is the first double-blind placebo controlled trial of icatibant in early COVID-19. Single dose icatibant therapy did not improve oxygenation or MAP in acute COVID-19. Trial registration Clinicaltrials.gov NCT05407597
Authors: Melanie Bailey, Dermot Linden, Hong Guo-Parke, Olivia Earley, Tunde Peto, Daniel Francis Mcauley, Clifford Taggart, Joseph Kidney
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4416636079
Cites:
Cited by:
Related to: